SARS-CoV-2 antibodies and breakthrough infections in the Virus Watch cohort.
SARS-CoV-2 antibodies and breakthrough infections in the Virus Watch cohort.
复制标题
DOI：
10.1038/s41467-022-32265-5
复制
发表时间：
2022-08-18
影响因子：
16.6
通讯作者：
Hayward, Andrew
中科院分区：
文献类型：
--
作者：
Aldridge, Robert W.;Yavlinsky, Alexei;Nguyen, Vincent;Eyre, Max T.;Shrotri, Madhumita;Navaratnam, Annalan M. D.;Beale, Sarah;Braithwaite, Isobel;Byrne, Thomas;Kovar, Jana;Fragaszy, Ellen;Fong, Wing Lam Erica;Geismar, Cyril;Patel, Parth;Rodger, Alison;Johnson, Anne M.;Hayward, Andrew
全球范围内的一系列研究表明，SARS-CoV-2疫苗的有效性随着时间的推移而减弱，但抗S抗体水平对SARS-CoV-2感染风险的总体影响以及这种影响是否因疫苗类型而异尚不清楚。在这里，我们表明抗S水平在第二剂疫苗后3至4周达到峰值，并且BNT 162 b2的样品几何平均值比ChAdOx 1高9倍。抗S抗体水平升高与SARS-CoV-2感染风险降低相关（风险比0.85; 95%CI：0.79-0.92）。我们没有发现证据表明这种抗体与感染风险的关系因第二剂疫苗类型（BNT 162 b2与ChAdOx 1）而异。与我们的抗S抗体数据一致，我们发现与BNT 162 b2相比，接种ChAdOx 1疫苗的人突破感染的几率是1.64倍（95%置信区间1.45-1.85）。我们预计我们的研究结果是有用的抗S水平的保护作用，由于三角洲感染的风险估计。我们的研究结果提供了关于抗体水平与不同疫苗保护之间关系的证据，并将支持优化加强疫苗接种时机的决策，并确定应优先进行加强疫苗接种的个体，包括年龄较大，临床上极其脆弱或接受ChAdOx 1作为主要疗程的个体。我们的发现，抗S水平的感染风险与疫苗类型没有相互作用，但接种ChAdOx 1的个体感染风险更高，这为使用抗S水平估计疫苗效力提供了额外的支持。在本文中，作者提供了来自病毒观察研究（19，556名成年人）的子队列的数据，他们每月完成家庭毛细血管血液采样，并描述了抗刺突抗体水平与SARS-CoV-2感染风险之间的关联。
A range of studies globally demonstrate that the effectiveness of SARS-CoV-2 vaccines wane over time, but the total effect of anti-S antibody levels on risk of SARS-CoV-2 infection and whether this varies by vaccine type is not well understood. Here we show that anti-S levels peak three to four weeks following the second dose of vaccine and the geometric mean of the samples is nine fold higher for BNT162b2 than ChAdOx1. Increasing anti-S levels are associated with a reduced risk of SARS-CoV-2 infection (Hazard Ratio 0.85; 95%CIs: 0.79-0.92). We do not find evidence that this antibody relationship with risk of infection varies by second dose vaccine type (BNT162b2 vs. ChAdOx1). In keeping with our anti-S antibody data, we find that people vaccinated with ChAdOx1 had 1.64 times the odds (95% confidence interval 1.45-1.85) of a breakthrough infection compared to BNT162b2. We anticipate our findings to be useful in the estimation of the protective effect of anti-S levels on risk of infection due to Delta. Our findings provide evidence about the relationship between antibody levels and protection for different vaccines and will support decisions on optimising the timing of booster vaccinations and identifying individuals who should be prioritised for booster vaccination, including those who are older, clinically extremely vulnerable, or received ChAdOx1 as their primary course. Our finding that risk of infection by anti-S level does not interact with vaccine type, but that individuals vaccinated with ChAdOx1 were at higher risk of infection, provides additional support for the use of using anti-S levels for estimating vaccine efficacy. Here the authors provide data from a sub-cohort of the Virus Watch study (19,556 adults) who completed at-home capillary blood sampling on a monthly basis and describe an association between anti-spike antibody levels and risk of SARS-CoV-2 infection.
登录
查看更多内容
影响因子：
64.8
作者：
Gaebler C;Wang Z;Lorenzi JCC;Muecksch F;Finkin S;Tokuyama M;Cho A;Jankovic M;Schaefer-Babajew D;Oliveira TY;Cipolla M;Viant C;Barnes CO;Bram Y;Breton G;Hägglöf T;Mendoza P;Hurley A;Turroja M;Gordon K;Millard KG;Ramos V;Schmidt F;Weisblum Y;Jha D;Tankelevich M;Martinez-Delgado G;Yee J;Patel R;Dizon J;Unson-O'Brien C;Shimeliovich I;Robbiani DF;Zhao Z;Gazumyan A;Schwartz RE;Hatziioannou T;Bjorkman PJ;Mehandru S;Bieniasz PD;Caskey M;Nussenzweig MC
通讯作者：
Nussenzweig MC
影响因子：
64.8
作者：
Liu J;Chandrashekar A;Sellers D;Barrett J;Jacob-Dolan C;Lifton M;McMahan K;Sciacca M;VanWyk H;Wu C;Yu J;Collier AY;Barouch DH
通讯作者：
Barouch DH
影响因子：
82.9
作者：
Gao Y;Cai C;Grifoni A;Müller TR;Niessl J;Olofsson A;Humbert M;Hansson L;Österborg A;Bergman P;Chen P;Olsson A;Sandberg JK;Weiskopf D;Price DA;Ljunggren HG;Karlsson AC;Sette A;Aleman S;Buggert M
通讯作者：
Buggert M
影响因子：
64.5
作者：
Liu C;Ginn HM;Dejnirattisai W;Supasa P;Wang B;Tuekprakhon A;Nutalai R;Zhou D;Mentzer AJ;Zhao Y;Duyvesteyn HME;López-Camacho C;Slon-Campos J;Walter TS;Skelly D;Johnson SA;Ritter TG;Mason C;Costa Clemens SA;Gomes Naveca F;Nascimento V;Nascimento F;Fernandes da Costa C;Resende PC;Pauvolid-Correa A;Siqueira MM;Dold C;Temperton N;Dong T;Pollard AJ;Knight JC;Crook D;Lambe T;Clutterbuck E;Bibi S;Flaxman A;Bittaye M;Belij-Rammerstorfer S;Gilbert SC;Malik T;Carroll MW;Klenerman P;Barnes E;Dunachie SJ;Baillie V;Serafin N;Ditse Z;Da Silva K;Paterson NG;Williams MA;Hall DR;Madhi S;Nunes MC;Goulder P;Fry EE;Mongkolsapaya J;Ren J;Stuart DI;Screaton GR
通讯作者：
Screaton GR
DOI：
10.1016/s1473-3099(20)30634-4
发表时间：
2020-12
期刊：
The Lancet. Infectious diseases
影响因子：
--
作者：
National SARS-CoV-2 Serology Assay Evaluation Group
通讯作者：
National SARS-CoV-2 Serology Assay Evaluation Group